Novo Nordisk shares fell sharply after the Danish drugmaker said an experimental obesity treatment failed to beat the weight loss delivered by Eli Lilly’s Zepbound

8 hours ago 1

The CagriSema survey results mark a setback for the drugmaker as it seeks to regain crushed mislaid to Eli Lilly successful the obesity-drug market.